ADAP: Adaptimmune - Transforming T-Cell therapy
Seite 74 von 74 Neuester Beitrag: 15.05.24 17:47 | ||||
Eröffnet am: | 09.05.15 11:08 | von: iTechDachs | Anzahl Beiträge: | 2.838 |
Neuester Beitrag: | 15.05.24 17:47 | von: iTechDachs | Leser gesamt: | 657.718 |
Forum: | Börse | Leser heute: | 424 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 68 | 69 | 70 | 71 | 72 | 73 | > |
mit Adrian Rawcliffe dazu geführt, in dem dieser auch zur Auflösung des Genentech Deals Stellung bezieht. Für ihn ist bis auf weiteres die autologe Zelltherapie die beste TCR T-Zelltherapie gegen Krebs und allogene Lösungen aktuell noch keine Alternative.
Die Auflösung des Deals spielt daher für die Zulassung und Vermarktung von Afami-cel keine Rolle.
und deren Mutter Roche - die Strategie zu ändern, z.B. die Änderungen in der US Politik:
"Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. siehe "Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
PLENARY KEYNOTE: Afami-cel: The Journey from TCR Engineering towards Commercial Cell Therapy
Joanna Brewer, PhD, CSO, Adaptimmune R&D
Afami-cel is a first-generation engineered TCR T cell product targeting MAGE-A4 expressing solid tumours. Afami-cel has the potential to be the first marketed product of its kind and Adaptimmune is close to completing its BLA submission. Afami-cel has demonstrated substantial clinical benefit for people with synovial sarcoma who have had multiple prior lines of therapy. This is the story of afami-cel from early discovery through clinical development and commercial strategy.
https://www.immuno-oncologyeurope.com/t-cell-therapy
Download as PDFMay 15, 2024 7:00am EDT
First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company's balance sheet as it executes on its sarcoma franchise with the commercial launch of afami-cel later this year and lete-cel planned for 2026. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) today to report its Q1 financial and business updates..."
https://www.adaptimmune.com/investors-and-media/...ebt-financing-with